Defying the weak market sentiment, pharma major Cipla today notched up 2.46% gain on BSE after the company slashed the prices of its generic drugs, used in treating cancers of brain, lung and kidney by up to 76%.
Cipla shares were up 2.46% at Rs 325.20 on the BSE. During the day, the stock jumped up by 3.65% to Rs 329.
At the wide-based National Stock Exchange, the stock gained 2.85% to settle at Rs 326.70.
Cipla was the best performing scrip amid the 30-Sensex blue-chips wherein 25 of its components ended in the negative territory.
The price of 'Soranib' used for treating kidney cancer has been cut by 76% to Rs 1,710 "for a month's therapy", from Rs 6,990, Cipla had said.
The move comes on the back of the government permitting domestic firm Natco Pharma to manufacture and sell cancer treatment drug Nexavar at a price over 30 times lower than charged by its patent-holder Bayer Corporation.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app